HemOnc Today Current Issue
The following articles appeared in the print edition of HemOnc Today.
Table of Contents
- How can physicians heighten awareness of HPV-related head and neck cancer?
-
- HPV is changing the face of head and neck cancers
- Adding tirapazamine to chemoradiotherapy showed no improvement for head and neck cancers
- Comparable results seen with substitution of paclitaxel for cyclophosphamide in high-risk breast cancer
- Douglas Yee, MD, explores IGF system and breast cancer
- Phase 2 paclitaxel, carboplatin and bortezomib trial stopped accrual early due to toxicity, limited benefit
- Study suggests timing of examinations to detect first stage III melanoma relapse
- Tanning bed use associated with 74% increased risk for melanoma
- Time to turn attention to post-thrombotic syndrome
-
- Targeted therapy for metastatic melanoma: From bench to bedside Wen-Jen Hwu, MD, PhD
- Adding lomustine to induction therapy improved outcomes in elderly patients with AML
- Chemotherapy combined with dasatinib associated with long term remission in Ph+ALL
- Combination chemotherapy regimen provided the most benefit for triple-negative breast cancer
- Factor V Leiden associated with higher levels of soluble fibrin, may lead to a more sustained activation of fibrinolysis
- HCT comorbidity index, CRP helped select CML patient candidates for HSCT
- Regular NSAID use may protect H. pylori-infected patients against gastric cancer
- ASCO issues guideline for the use of tumor markers for men with germ cell tumors
-
- Botox treatment improved lower urinary tract symptoms in patients with bladder cancer
- Dogs recognized presence of prostate cancer in urine samples
- Nanotechnology-enabled PSA assay may be useful in stratifying patients post-prostatectomy
- Preoperative mitomycin-C decreased risk for non-muscle invasive bladder cancer recurrence
- New recommendations for the treatment of C. difficile infections Lisa K. Lohr, PharmD, BCPS, BCOP